argenx SE(ARGX) Stock Research - Grey Stern Research

argenx SE (ARGX) Stock Analysis

$542.99 (-1.27%)

ARGX Financial Performance


Use the table below to view argenx SE's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $550.00 -
52 Week Low $327.73 -
52 Week High $554.74 -
Market Cap $32.9 Billion 3/16
Gross Margin 89% 6/16
Profit Margin -4% 6/16
EBITDA margin -17% 4/16
Q2 - 2024 Revenue $877.3 Million 2/16
Q2 - 2024 Earnings -$32.5 Million 5/16
Q2 - 2024 Free Cash Flow -$98.3 Million 11/16
Trailing 4 Quarters Revenue $2.0 Billion 4/16
Trailing 4 Quarters Earnings -$266.1 Million 7/16
Quarterly Earnings Growth 66% 6/16
Annual Earnings Growth -47% 14/16
Quarterly Revenue Growth 224% 1/16
Annual Revenue Growth 117% 4/16
Cash On Hand $1.4 Billion 2/16
Short Term Debt $5.9 Million 9/16
Long Term Debt $0 14/16

argenx SE Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare argenx SE's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 1/16
PS 16.31 7/16
PB 7.72 8/16
PC 22.87 8/16
Liabilities to Equity 0.13 11/16
ROA -0.06 2/16
ROE -0.06 3/16
Current Ratio 8.98 4/16
Quick Ratio 5.81 4/16
Long Term Debt to Equity 0.00 12/16
Debt to Equity 0.01 10/16
Burn Rate 42.37 2/16
Cash to Cap 0.04 8/16
CCR 3.03 2/16
EV to EBITDA -209.87 14/16
EV to Revenue 15.62 8/16

Company Details

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

CEO: Mr. Tim Van Hauwermeiren

Website: https://www.argenx.com

Address: Willemstraat 5 Breda,

Exchange: NASDAQ Global Select

Industry: Biotechnology

argenx SE Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to argenx SE. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Alnylam Pharmaceuticals, Inc. ALNY $34.9 Billion
BeiGene, Ltd. BGNE $26.8 Billion
Seagen Inc. SGEN $43.2 Billion
Mirati Therapeutics, Inc. MRTX $4.1 Billion
Blueprint Medicines Corporation BPMC $5.7 Billion
Apellis Pharmaceuticals, Inc. APLS $3.5 Billion
Zai Lab Limited ZLAB $2.5 Billion
Ascendis Pharma A/S ASND $8.4 Billion
IVERIC bio, Inc. ISEE $5.5 Billion
Karuna Therapeutics, Inc. KRTX $12.6 Billion
Legend Biotech Corporation LEGN $8.9 Billion
Vaxcyte, Inc. PCVX $13.9 Billion
Travere Therapeutics, Inc. TVTX $1.1 Billion
Terns Pharmaceuticals, Inc. TERN $692.4 Million
Day One Biopharmaceuticals, Inc. DAWN $1.2 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ARGX Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 877.3 Million -$32.5 Million
Q1 2024 $ 401.0 Million -$61.6 Million
Q4 2023 $ 737.7 Million -$172.1 Million
Q3 2023 $ 0 $0
Q2 2023 $ 270.6 Million -$94.4 Million
Q1 2023 $ 219.1 Million -$28.9 Million
Q4 2022 $ 174.2 Million -$38.6 Million
Q3 2022 $ 138.0 Million -$235.0 Million

View All

ARGX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $1.4 Billion $4.8 Billion $34.0 Million $4.3 Billion
Q1 2024 $2.9 Billion $0 $0 $3.8 Billion
Q4 2023 $2.0 Billion $4.5 Billion $20.0 Million $4.1 Billion
Q3 2023 $1.9 Billion $0 $0 $2.7 Billion
Q2 2023 $1.1 Billion $3.2 Billion $11.2 Million $2.9 Billion
Q1 2023 $0 $0 $0 $0
Q4 2022 $800.7 Million $3.1 Billion $12.4 Million $2.8 Billion
Q3 2022 $2.7 Billion $0 $0 $3.0 Billion

View All

ARGX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 -$98.3 Million -$22.3 Million -$610.6 Million
Q1 2024 $0 $0 $0
Q4 2023 -$113.0 Million -$43.4 Million $938.3 Million
Q3 2023 $0 $0 $0
Q2 2023 -$259.0 Million -$479,781 $263.7 Million
Q1 2023 $0 $0 $0
Q4 2022 -$835.7 Million -$793,343 -$452.4 Million
Q3 2022 $0 $0 $0

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions